<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146900</url>
  </required_header>
  <id_info>
    <org_study_id>21-27.06.03-HMO-CTIL</org_study_id>
    <secondary_id>MH-</secondary_id>
    <nct_id>NCT00146900</nct_id>
  </id_info>
  <brief_title>Prevention of Post Traumatic Stress Disorder by Early Treatment</brief_title>
  <official_title>Prevention of Post Traumatic Stress Disorder by Early Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively evaluate the effect of early treatment (cognitive therapy (CT),
      cognitive-behavioral therapy (CBT) and escitalopram (SSRI) in preventing the occurrence of
      post-traumatic stress disorder in recent survivors of traumatic events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive civilian trauma survivors will be contacted, by phone, within five days of
      admission to Hadassah University Hospital in Jerusalem and asked about their early
      psychological responses to the event. A short telephone interview will be administered to
      consenting subjects, to evaluate the presence of acute stress disorder (ASD). Subjects with
      ASD (full or partial) and those who so desire will be invited to clinical assessment, which
      will take place within the next two weeks. Survivors with significant symptoms of
      post-traumatic stress disorder will be randomized to five arms of twelve-week long treatment:
      CBT, CT, SSRI/placebo and waiting list (WL) and start treatment immediately. Subjects will be
      allowed to decline one form of therapy. WL subjects will start therapy 12 weeks later. All
      subjects who had clinical interview will be interviewed again at four and seven months - and
      14 months following trauma (phone interview).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-traumatic Stress Disorder (chronic) by CAPS scores.</measure>
    <time_frame>Four months, seven months, 14 moths, two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms of post-traumatic Stress Disorder per PSS-SR (questionnaire) and CAPS (structured interview)</measure>
    <time_frame>Four months, seven months, 14 moths, two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of depression as per the Beck Depression Inventory (BDI)</measure>
    <time_frame>Four months, seven months, 14 moths, two years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Prolonged Exposure (CBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve 1.5 hours weekly sessions of Prolonged Exposure cognitive behavioral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twelve 1.5 hours weekly sessions of Cognitive Therapy without exposure to traumatic reminders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSRI (escitalopram)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twenty milligrams daily of escitalopram (blinded capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two concealed placebo pills resembling 10mg escitalopram tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waiting List</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Twelve weeks of waiting list no intervention group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)</description>
    <arm_group_label>Prolonged Exposure (CBT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cognitive Therapy</intervention_name>
    <description>12 weekly 1.5 hours weekly session of cognitive therapy without exposure</description>
    <arm_group_label>Cognitive Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg</description>
    <arm_group_label>SSRI (escitalopram)</arm_group_label>
    <other_name>SSRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults survivors of traumatic events

        Exclusion Criteria:

          -  Traumatic brain injury

          -  Lifetime psychosis

          -  Life time (prior) PTSD

          -  Medical conditions forbidding SSRIs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arieh Y Shalev, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yossi Israeli - Shalev, M.A.</last_name>
    <role>Study Director</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization Jerusalem Israel</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Shalev AY, Ankri YL, Peleg T, Israeli-Shalev Y, Freedman S. Barriers to receiving early care for PTSD: results from the Jerusalem trauma outreach and prevention study. Psychiatr Serv. 2011 Jul;62(7):765-73. doi: 10.1176/ps.62.7.pss6207_0765.</citation>
    <PMID>21724790</PMID>
  </results_reference>
  <results_reference>
    <citation>Shalev AY, Ankri Y, Israeli-Shalev Y, Peleg T, Adessky R, Freedman S. Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem Trauma Outreach And Prevention study. Arch Gen Psychiatry. 2012 Feb;69(2):166-76. doi: 10.1001/archgenpsychiatry.2011.127. Epub 2011 Oct 3.</citation>
    <PMID>21969418</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2005</study_first_submitted>
  <study_first_submitted_qc>September 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Aria Shalev</investigator_full_name>
    <investigator_title>Emeritus Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Traumatic Events</keyword>
  <keyword>Post-traumatic Stress Disorder</keyword>
  <keyword>Treatment (psychological)</keyword>
  <keyword>Treatment (pharmacological)</keyword>
  <keyword>Prevention</keyword>
  <keyword>SSRIs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

